Cartesian Therapeutics, Inc.RNACNASDAQ
LOADING
|||
Switch Symbol:
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
3.42%
↑ 117% above average
Average (39q)
-20.57%
Historical baseline
Range
High:307.11%
Low:-535.62%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 3.42% |
| Q2 2025 | 0.36% |
| Q1 2025 | 18.11% |
| Q4 2024 | -52.10% |
| Q3 2024 | -227.75% |
| Q2 2024 | 203.06% |
| Q1 2024 | 63.26% |
| Q4 2023 | -178.09% |
| Q3 2023 | 29.90% |
| Q2 2023 | -1.40% |
| Q1 2023 | -116.35% |
| Q4 2022 | -431.33% |
| Q3 2022 | -111.54% |
| Q2 2022 | 28.65% |
| Q1 2022 | 164.17% |
| Q4 2021 | 307.11% |
| Q3 2021 | -535.62% |
| Q2 2021 | 106.31% |
| Q1 2021 | 9.37% |
| Q4 2020 | 42.49% |
| Q3 2020 | 16.09% |
| Q2 2020 | 13.04% |
| Q1 2020 | -49.74% |
| Q4 2019 | -6.58% |
| Q3 2019 | 27.35% |
| Q2 2019 | -36.93% |
| Q1 2019 | 18.23% |
| Q4 2018 | 9.05% |
| Q3 2018 | 15.07% |
| Q2 2018 | -18.69% |
| Q1 2018 | 17.97% |
| Q4 2017 | -39.14% |
| Q3 2017 | 12.71% |
| Q2 2017 | -7.37% |
| Q1 2017 | -6.65% |
| Q4 2016 | -85.59% |
| Q3 2016 | -16.67% |
| Q2 2016 | 7.78% |
| Q1 2016 | 2.34% |
| Q4 2015 | -17.06% |